South & Central America Glycomic Therapeutics Market Forecast to 2028

South & Central America Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]

Report Code : BMIRE00027517 | Region : LAMEA | Industry : Pharmaceuticals | Published Date : 18/Nov/2022

The glycomic therapeutics market in South & Central America is expected to grow from US$ 8,651.70 million in 2022 to US$ 20,683.58 million by 2028; it is estimated to grow at a CAGR of 14.5% from 2022 to 2028.

Application in Treatment of Broad Range of Disorders Drives Market Growth

Glycan-based products have wide applications in the therapeutic industry; the products are available in different structures & forms and developed as per the application. This drug is designed for various diseases, such as thrombosis, anaemia, cancer, influenza, cataract, and anti-inflammation. The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells. Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used and are a part of several research projects. These products are aimed at expanding and improving their applicability and efficacy. EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer's disease in rodent models due to its known neuroprotective effects. The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions.

For instance, in April 2020, researchers from the Institute for Glycomics and the University of Adelaide signed an exclusive licensing agreement with Sienna Cancer Diagnostics Ltd. to commercialize a cutting-edge cancer detection tool. The researchers have created SubB2M, a special protein that attaches itself exclusively to a sugar molecule, only found in cancer cells. The researchers have claimed that the protein might revolutionize cancer detection.

In March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US$ 800,000 for peptide drug development utilizing its unique drug discovery platform. The CQDM Quantum Leap initiative, which encourages research into cutting-edge technologies, methods, and platforms that speed up or expedite drug discovery and development, provided funding for the two-year study. Merck, a CQDM member, is financing the study. The University of Alberta and 48HD will work together on the project. Additionally, GlycoNet, a Network of Centres of Excellence centered at the University of Alberta for Glycomics Research, is providing the funds to enhance the quality of life of Canadians.

In March 2022, researchers from the Canadian Glycomics Network (GlycoNet) developed a novel combination medication for Sanfilippo syndrome, which is showing encouraging preclinical outcomes. Researchers at Kaleido Biosciences are developing therapeutics for immune-mediated and inflammatory diseases with synthetic glycans that are selectively metabolized in the gut microbiome to suppress the growth of bacteria associated with inflammation. One synthetic glycan candidate, KB295, is intended to treat ulcerative colitis, an inflammatory bowel disorder (IBD). The administration of microbiome-mediating glycans could radically improve treatment by 16% of IBD sufferers who do not respond to the current standard of care and other patients with hard-to-treat autoimmune and inflammatory conditions. These advancements show that glycomics has the potential to provide rapid and accurate therapeutic results for complex conditions. Therefore, the use of glycomics in drug development for diseases across the region drives the glycomics therapeutics market.

Market Overview

The South & Central America glycomic therapeutics market is segmented into Brazil, Argentina, and the Rest of South & Central America. The glycomic therapeutics market in South & Central America is expected to grow due to the growing pharmaceutical industry landscape, rising healthcare expenditure, and growing education programs and conferences.

South & Central America Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)

South & Central America Glycomic Therapeutics Market Segmentation

The South & Central America glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the South & Central America glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the South & Central America glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the South & Central America glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher’s disease, MPS-1 & IV, cancer, alzheimer’s disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the South & Central America glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the South & Central America glycomic therapeutics market is segmented into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America dominated the market in 2022. BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Bayer AG; Alzheon, Inc.; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics in South & Central America.

TABLE OF CONTENTS

1. Introduction

1.1 Study Scope

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 South & Central America Glycomic Therapeutics Market – By Class

1.3.2 South & Central America Glycomic Therapeutics Market – By Structures

1.3.3 South & Central America Glycomic Therapeutics Market – By Indications

1.3.4 South & Central America Glycomic Therapeutics Market – By Mode of Action

1.3.5 South & Central America Glycomic Therapeutics Market – By Country

2. South & Central America Glycomic Therapeutics Market– Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. South & Central America Glycomic Therapeutics Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 South & Central America – PEST Analysis

4.3 Expert Opinion

5. South & Central America Glycomic Therapeutics Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes

5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics

5.2 Market Restraints

5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.

5.3 Market Opportunities

5.3.1 Wide Applications of Glycomics in Therapeutics

5.4 Future Trends

5.4.1 New Tools in Glycomics Research

5.5 Impact Analysis

6. Glycomic Therapeutics Market– South & Central America Analysis

6.1 South & Central America Glycomic Therapeutics Market Revenue Forecast and Analysis

6.1.1 South & Central America: Glycomic Therapeutics Market Revenue and Forecasts to 2028, (US$ Million)

7. South & Central America Glycomic Therapeutics Market Revenue and Forecast to 2028– by Class

7.1 Overview

7.2 South & Central America Glycomic Therapeutics Market, By Class 2022 & 2028 (%)

7.2.1 South & Central America: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

7.3 Isolated

7.3.1 Overview

7.3.2 South & Central America Isolated Revenue and Forecast to 2028 (US$ Million)

7.4 Synthetic

7.4.1 Overview

7.4.2 South & Central America Synthetic - Revenue and Forecast to 2028 (US$ Million)

8. South & Central America Glycomics Therapeutics Market Analysis and Forecasts To 2028 – By Indication

8.1 Overview

8.2 South & Central America Glycomics Market, By Indication 2022 & 2028 (%)

8.2.1 South & Central America: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

8.3 Thrombosis and Chemoprophylaxis

8.3.1 Overview

8.3.2 South & Central America Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US$ Million)

8.4 Anaemia

8.4.1 Overview

8.4.2 South & Central America Anaemia Revenue and Forecast to 2028 (US$ Million)

8.5 Anti-adhesive and Anti-inflammatory

8.5.1 Overview

8.5.2 South & Central America Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US$ Million)

8.6 Cataract

8.6.1 Overview

8.6.2 South & Central America Cataract Revenue and Forecast to 2028 (US$ Million)

8.7 Gaucher’s diseases

8.7.1 Overview

8.7.2 South & Central America Gaucher’s diseases Revenue and Forecast to 2028 (US$ Million)

8.8 MPS-1 & IV

8.8.1 Overview

8.8.2 South & Central America MPS-1 & IV Revenue and Forecast to 2028 (US$ Million)

8.9 Cancer

8.9.1 Overview

8.9.2 South & Central America Cancer Revenue and Forecast to 2028 (US$ Million)

8.10 Alzheimer's

8.10.1 Overview

8.10.2 South & Central America Alzheimer's Revenue and Forecast to 2028 (US$ Million)

8.11 Influenza Type A and B

8.11.1 Overview

8.11.2 South & Central America Influenza Type A and B Revenue and Forecast to 2028 (US$ Million)

8.12 Others

8.12.1 Overview

8.12.2 South & Central America Others Revenue and Forecast to 2028 (US$ Million)

9. South & Central America Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Structures

9.1 Overview

9.2 South & Central America Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)

9.2.1 South & Central America: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

9.2.1.1 South & Central America: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

9.2.1.2 South & Central America: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

9.2.1.3 South & Central America: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

9.2.1.4 South & Central America: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

9.3 Glycoproteins

9.3.1 Overview

9.3.2 South & Central America Glycoproteins - Market Revenue and Forecast to 2028 (US$ Million)

9.4 Targeting Sialic Acid

9.4.1 Overview

9.4.2 South & Central America Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US$ Million)

9.4.3 Zanamivir

9.4.3.1 Overview

9.4.3.2 South & Central America Zanamivir - Market Revenue and Forecast to 2028 (US$ Million)

9.4.4 Oseltamivir

9.4.4.1 Overview

9.4.4.2 South & Central America Oseltamivir - Market Revenue and Forecast to 2028 (US$ Million)

9.5 Proteoglycans

9.5.1 Overview

9.5.2 South & Central America Proteoglycans - Market Revenue and Forecast to 2028 (US$ Million)

9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans

9.6.1 Overview

9.6.2 South & Central America Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US$ Million)

9.7 Targeting Glycosaminoglycans

9.7.1 Overview

9.7.2 South & Central America Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US$ Million)

9.7.3 Heparin

9.7.3.1 Overview

9.7.3.2 South & Central America Heparin - Market Revenue and Forecast to 2028 (US$ Million)

9.7.4 Hyaluronan (HA)

9.7.4.1 Overview

9.7.4.2 South & Central America Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US$ Million)

9.7.5 Laronidase

9.7.5.1 Overview

9.7.5.2 South & Central America Laronidase - Market Revenue and Forecast to 2028 (US$ Million)

9.7.6 Galsulfase (Naglazyme)

9.7.6.1 Overview

9.7.6.2 South & Central America Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.7.7 Hyaluronidase (Cumulase)

9.7.7.1 Overview

9.7.7.2 South & Central America Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US$ Million)

9.7.8 Others

9.7.8.1 Overview

9.7.8.2 South & Central America Others - Market Revenue and Forecast to 2028 (US$ Million)

9.8 Targeting Glycosphingolipids

9.8.1 Overview

9.8.2 South & Central America Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US$ Million)

9.8.3 Imiglucerase (Cerezyme)

9.8.3.1 Overview

9.8.3.2 South & Central America Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US$ Million)

9.8.3.3 Agalsidase (Fabrazyme)

9.8.3.3.1 Overview

9.8.3.3.2 South & Central America Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.8.3.4 N-butyl-deoxynojirimycin (DNJ)

9.8.3.4.1 Overview

9.8.3.4.2 South & Central America N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US$ Million)

9.8.4 Others

9.8.4.1 Overview

9.8.4.2 South & Central America Others - Market Revenue and Forecast to 2028 (US$ Million)

9.9 Others

9.9.1 Overview

9.9.2 South & Central America Others - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3 Acarbose

9.9.3.1 Overview

9.9.3.2 South & Central America Acarbose - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3.3 Alglucosidase Alfa (Myozyme)

9.9.3.3.1 Overview

9.9.3.3.2 South & Central America Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3.4 Allosamidin

9.9.3.4.1 Overview

9.9.3.4.2 South & Central America Allosamidin - Market Revenue and Forecast to 2028 (US$ Million)

9.9.4 Others

9.9.4.1 Overview

9.9.4.2 South & Central America Others - Market Revenue and Forecast to 2028 (US$ Million)

10. South & Central America Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Mode of Action

10.1 Overview

10.2 South & Central America Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)

10.2.1 South & Central America: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

10.3 Inhibits Neuraminidase

10.3.1 Overview

10.3.2 South & Central America Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US$ Million)

10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate

10.4.1 Overview

10.4.2 South & Central America Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US$ Million)

10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)

10.5.1 Overview

10.5.2 South & Central America Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US$ Million)

10.6 Tissue Plasminogen Activator

10.6.1 Overview

10.6.2 South & Central America Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)

10.7 Inhibits Glucosylceramide Synthase

10.7.1 Overview

10.7.2 South & Central America Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)

10.8 Interleukin 1 And 2 And 3

10.8.1 Overview

10.8.2 South & Central America Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)

10.9 Beta And Gamma Interferons

10.9.1 Overview

10.9.2 South & Central America Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US$ Million)

10.10 Others

10.10.1 Overview

10.10.2 South & Central America Others- Market Revenue And Forecasts To 2028 (US$ Million)

11. South & Central America Glycomic Therapeutics Market Revenue and Forecasts to 2028 – Country Analysis

11.1 South & Central America: Glycomic Therapeutics Market

11.1.1 Overview

11.1.2 South & Central America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)

11.1.2.1 Brazil: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.2.1.1 Brazil: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.2.1.2 Brazil: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.2.1.3 Brazil: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.2.1.3.1 Brazil: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.2.1.3.2 Brazil: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.2.1.3.3 Brazil: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.2.1.3.4 Brazil: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.2.1.4 Brazil: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.2.1.5 Brazil: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.2.2 Argentina: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.2.2.1 Argentina: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.2.2.2 Argentina: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.2.2.3 Argentina: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.2.2.3.1 Argentina: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.2.2.3.2 Argentina: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.2.2.3.3 Argentina: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.2.2.3.4 Argentina: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.2.2.4 Argentina: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.2.2.5 Argentina: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.2.3 Rest of South and Central America: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.2.3.1 Rest of SCAM: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.2.3.2 Rest of SCAM: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.2.3.3 Rest of SCAM: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.2.3.3.1 Rest of SCAM: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.2.3.3.2 Rest of SCAM: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.2.3.3.3 Rest of SCAM: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.2.3.3.4 Rest of SCAM: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.2.3.4 Rest of SCAM: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.2.3.5 Rest of SCAM: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

12. South & Central America Glycomic Therapeutics Market –Industry Landscape

12.1 Overview

12.2 Growth Strategies in the Glycomic Therapeutics Market (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

13.1 BioMarin Pharmaceutical Inc.

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Genzyme Corporation (Sanofi)

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Bayer AG

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 GlaxoSmithKline plc.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 F. Hoffmann-La Roche Ltd

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms in Glycomic Therapeutics Market

LIST OF TABLES.

Table 1. South & Central America: Glycomic Therapeutics Market Revenue and Forecasts to 2028, (US$ Million)

Table 2. South & Central America Glycomic Therapeutics Market, by C lass – Revenue and Forecast to 2028 (US$ Million)

Table 3. South & Central America Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 4. South & Central America Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)

Table 5. South & Central America Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)

Table 6. South & Central America Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)

Table 7. South & Central America Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)

Table 8. South & Central America Glycomic Therapeutics Market, by Others– Revenue and Forecast to 2028 (USD Million)

Table 9. South & Central America Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)

Table 10. Brazil Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 11. Brazil Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 12. Brazil Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 13. Brazil Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 14. Brazil Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 15. Brazil Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 16. Brazil Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 17. Brazil Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 18. Argentina Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 19. Argentina Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 20. Argentina Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 21. Argentina Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 22. Argentina Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 23. Argentina Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 24. Argentina Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 25. Argentina Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 26. Rest of SCAM Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 27. Rest of SCAM Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 28. Rest of SCAM Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 29. Rest of SCAM Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 30. Rest of SCAM Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 31. Rest of SCAM Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 32. Rest of SCAM Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 33. Rest of SCAM Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 34. Organic Developments in the Glycomic Therapeutics Market

Table 35. Inorganic Developments in the Glycomic Therapeutics Market

Table 36. Glossary of Terms in Glycomic Therapeutics Market

LIST OF FIGURES.

Figure 1. South & Central America Glycomic Therapeutics Market Segmentation

Figure 2. South & Central America Glycomic Therapeutics Market, By Country

Figure 3. South & Central America Glycomic Therapeutics Market Overview

Figure 4. Synthetic Segment Held Largest Share of Class Segment in South & Central America Glycomic Therapeutics Market

Figure 5. Argentina is Expected to Show Remarkable Growth During the Forecast Period

Figure 6. South & Central America: PEST Analysis

Figure 7. South & Central America Glycomic Therapeutics Market Impact Analysis of Driver and Restraints

Figure 8. South & Central America Glycomics market – Revenue Forecast and Analysis – 2020- 2028

Figure 9. South & Central America Glycomic Therapeutics Market, by Class 2022 & 2028 (%)

Figure 10. South & Central America Isolated Revenue and Forecasts to 2028 (US$ Million)

Figure 11. South & Central America Synthetic - Revenue and Forecasts to 2028 (US$ Million)

Figure 12. South & Central America Glycomics Market, by Indication 2022 & 2028 (%)

Figure 13. South & Central America Thrombosis and chemoprophylaxis Revenue and Forecasts to 2028 (US$ Million)

Figure 14. South & Central America Anaemia Revenue and Forecasts to 2028 (US$ Million)

Figure 15. South & Central America Anti-adhesive and Anti-inflammatory Revenue and Forecasts to 2028 (US$ Million)

Figure 16. South & Central America Cataract Revenue and Forecasts to 2028 (US$ Million)

Figure 17. South & Central America Gaucher’s diseases Revenue and Forecasts to 2028 (US$ Million)

Figure 18. South & Central America MPS-1 & IV Revenue and Forecasts to 2028 (US$ Million)

Figure 19. South & Central America Cancer Revenue and Forecasts to 2028 (US$ Million)

Figure 20. South & Central America Alzheimer's Revenue and Forecasts to 2028 (US$ Million)

Figure 21. South & Central America Influenza Type A and B Revenue and Forecasts to 2028 (US$ Million)

Figure 22. South & Central America Others Revenue and Forecasts to 2028 (US$ Million)

Figure 23. South & Central America Glycomic Therapeutics Market, by Structures 2022 & 2028 (%)

Figure 24. South & Central America Glycoproteins - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 25. South & Central America Targeting Sialic Acid - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 26. South & Central America Zanamivir - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 27. South & Central America Oseltamivir - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 28. South & Central America Proteoglycans - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 29. South & Central America Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 30. South & Central America Targeting Glycosaminoglycans - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 31. South & Central America Heparin - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 32. South & Central America Hyaluronan (HA) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 33. South & Central America Laronidase - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 34. South & Central America Guillain-Barre Syndrome - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 35. South & Central America Hyaluronidase (Cumulase) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 36. South & Central America Others - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 37. South & Central America Targeting Glycosphingolipids - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 38. South & Central America Imiglucerase (Cerezyme )- Market Revenue and Forecasts to 2028 (US$ Million)

Figure 39. South & Central America Agalsidase (Fabrazyme) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 40. South & Central America N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 41. South & Central America Others - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 42. South & Central America Others - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 43. South & Central America Acarbose - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 44. South & Central America Alglucosidase Alfa (Myozyme) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 45. South & Central America Allosamidin - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 46. South & Central America Others - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 47. South & Central America Glycomic Therapeutics Market, by Mode of Action 2022 & 2028 (%)

Figure 48. South & Central America Inhibits Neuraminidase - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 49. South & Central America Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 50. South & Central America Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 51. South & Central America Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)

Figure 52. South & Central America Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)

Figure 53. South & Central America Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)

Figure 54. South & Central America Beta And Gamma Interferons - Market Revenue And Forecasts To 2028 (US$ Million)

Figure 55. South & Central America Others - Market Revenue And Forecasts To 2028 (US$ Million)

Figure 56. South and Central America: Glycomic Therapeutics Market, by Key Country – Revenue (2022) (US$ Million)

Figure 57. South & Central America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)

Figure 58. Brazil: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

Figure 59. Argentina: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

Figure 60. Rest of SCAM: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

Figure 61. Growth Strategies in the Glycomic Therapeutics Market (%)

The List of Companies - South & Central America Glycomic Therapeutics Market

● BioMarin Pharmaceutical Inc.

● Genzyme Corporation (Sanofi)

● Bayer AG

● GlaxoSmithKline plc.

● F. Hoffmann-La Roche Ltd

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America Glycomic Therapeutics Market.

● Highlights key business priorities in order to assist companies to realign their business strategies.

● The key findings and recommendations highlight crucial progressive industry trends in South & Central America Glycomic Therapeutics Market, thereby allowing players across the value chain to develop effective long-term strategies.

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

● Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the market, as well as those hindering it.

● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Back to Industry Report

Pricing
	$3,000.00	Single User Price
	$4,000.00	Site Price
	$5,000.00	Enterprise Price
Buy Now

South & Central America Glycomic Therapeutics Market Forecast to 2028 – COVID

Have Additional Questions?